Nixing antibody aggregation

Australian newco Solvanix Pty. Ltd. was founded last month on the basis of two amino acid changes in an antibody. The start-up expanded its early studies showing the altered residues transformed a misbehaving mAb into a viable candidate, and has created a technology for preventing antibody aggregation without incurring immunogenicity. Now the company is looking for biotechs and pharmas to license the technology.

Solvanix believes its strategy can solve common problems across the spectrum of antibody development, from early compound selection where aggregation causes good molecules to be screened out, to formulation of drugs for autoinjectors where the high concentrations and small volumes needed commonly result in protein aggregation...